Clinical Trials

295 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT05347134 2026-05-08

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

254 enrolled

Triple Negative Breast Neoplasms

NCT06081959 2026-05-08

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Phase 3 Recruiting

376 enrolled

Breast Neoplasms

NCT05171647 2026-05-07

SUNMO

Phase 3 Not yet recruiting

208 enrolled 12 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT07570823 2026-05-06

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

101 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT03456076 2026-05-05

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

257 enrolled 14 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05104866 2026-05-05

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT02542293 2026-05-01

NEPTUNE

953 enrolled 29 charts

Thoracic

Non Small Cell Lung Carcinoma NSCLC

NCT04241185 2026-05-01

MK-3475-992

520 enrolled

Urinary Bladder Neoplasms

NCT02486718 2026-04-30

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

1,280 enrolled 24 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06103864 2026-04-30

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Phase 3 Recruiting

625 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04384484 2026-04-28

LOTIS 5

440 enrolled

Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03967977 2026-04-23

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

420 enrolled

Carcinoma, Transitional Cell

NCT06960577 2026-04-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Phase 3 Recruiting

150 enrolled

Other solid neoplasmThoracic

Urinary Bladder Neoplasms

NCT03710876 2026-04-21

INFINITE

Phase 3 Completed

53 enrolled 23 charts

Mesothelioma, Malignant

NCT05771480 2026-04-21

TOURMALINE

142 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

770 enrolled 13 charts 1 FDA

Urothelial Cancer

NCT04083235 2026-04-20

NAPOLI 3

Phase 3 Completed

Gastrointestinal

Metastatic Adenocarcinoma of the Pancreas

NCT05911295 2026-04-20

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

412 enrolled